Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8158850rdf:typepubmed:Citationlld:pubmed
pubmed-article:8158850lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:8158850lifeskim:mentionsumls-concept:C0034902lld:lifeskim
pubmed-article:8158850lifeskim:mentionsumls-concept:C0037567lld:lifeskim
pubmed-article:8158850lifeskim:mentionsumls-concept:C0332281lld:lifeskim
pubmed-article:8158850lifeskim:mentionsumls-concept:C1533148lld:lifeskim
pubmed-article:8158850pubmed:issue3lld:pubmed
pubmed-article:8158850pubmed:dateCreated1994-5-18lld:pubmed
pubmed-article:8158850pubmed:abstractTextWe reported a 14-year-old female with petit mal epilepsy who suffered from pure red cell aplasia 12 weeks after sodium valproate (VPA) therapy started. On admission she presented anemia but no jaundice. Her hemoglobin was 5.4g/dl and bone-marrow biopsy revealed hypocellularity with erythroid hypoplasia. The Direct Coombs' test and anti-nucleotide antibody were positive. Reticulocytosis occurred 10 days after discontinuation of VPA. The Direct Coombs' test became negative one year after discontinuation of VPA. In general, drug-induced PRCA is caused by toxic or allergic agents, but this case suggests the immune mechanism of VPA-induced PRCA.lld:pubmed
pubmed-article:8158850pubmed:languagejpnlld:pubmed
pubmed-article:8158850pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8158850pubmed:citationSubsetIMlld:pubmed
pubmed-article:8158850pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8158850pubmed:statusMEDLINElld:pubmed
pubmed-article:8158850pubmed:monthMarlld:pubmed
pubmed-article:8158850pubmed:issn0485-1439lld:pubmed
pubmed-article:8158850pubmed:authorpubmed-author:KuboMMlld:pubmed
pubmed-article:8158850pubmed:authorpubmed-author:AnzaiKKlld:pubmed
pubmed-article:8158850pubmed:authorpubmed-author:KitajimaHHlld:pubmed
pubmed-article:8158850pubmed:issnTypePrintlld:pubmed
pubmed-article:8158850pubmed:volume35lld:pubmed
pubmed-article:8158850pubmed:ownerNLMlld:pubmed
pubmed-article:8158850pubmed:authorsCompleteYlld:pubmed
pubmed-article:8158850pubmed:pagination286-90lld:pubmed
pubmed-article:8158850pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:8158850pubmed:meshHeadingpubmed-meshheading:8158850-...lld:pubmed
pubmed-article:8158850pubmed:meshHeadingpubmed-meshheading:8158850-...lld:pubmed
pubmed-article:8158850pubmed:meshHeadingpubmed-meshheading:8158850-...lld:pubmed
pubmed-article:8158850pubmed:meshHeadingpubmed-meshheading:8158850-...lld:pubmed
pubmed-article:8158850pubmed:meshHeadingpubmed-meshheading:8158850-...lld:pubmed
pubmed-article:8158850pubmed:meshHeadingpubmed-meshheading:8158850-...lld:pubmed
pubmed-article:8158850pubmed:meshHeadingpubmed-meshheading:8158850-...lld:pubmed
pubmed-article:8158850pubmed:year1994lld:pubmed
pubmed-article:8158850pubmed:articleTitle[A case of pure red cell aplasia associated with sodium valproate therapy].lld:pubmed
pubmed-article:8158850pubmed:affiliationDepartment of Pediatrics, Jikei University School of Medicine.lld:pubmed
pubmed-article:8158850pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8158850pubmed:publicationTypeEnglish Abstractlld:pubmed
pubmed-article:8158850pubmed:publicationTypeCase Reportslld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8158850lld:pubmed